Published 1 year ago

Pfizer says RSV vaccine is effective at preventing severe illness in babies

Summary by Ground News

Preliminary results buoy hope that after decades of failure and frustration, vaccines against RSV may finally be getting close. New research shows vaccinating pregnant women helped protect their newborns from the common but scary respiratory virus called RSV that fills hospitals with wheezing babies each fall.

0 Articles

All

Left

Center

Right

CTV News

Strong RSV vaccine data lifts hopes after years of futility

New research shows vaccinating pregnant women helped protect their newborns from the common but scary respiratory virus called RSV that fills hospitals with wheezing babies each fall.

1 year ago·Canada

Read Full Article

Associated Press News

Strong RSV vaccine data lifts hopes after years of futility

New research shows vaccinating pregnant women helped protect their newborns from the common but scary respiratory virus called RSV that fills hospitals with wheezing babies each fall.

1 year ago·United States

Read Full Article

USA Today

Strong RSV vaccine data lifts hopes

New research shows vaccinating pregnant women helped protect their newborns from the common but scary respiratory virus called RSV that fills hospitals with wheezing babies each fall. (Nov. 1)

1 year ago·United States

Read Full Article

Global News

Vaccinating pregnant women with new RSV vaccine helped protect newborns: Pfizer - National

Pfizer's maternal vaccine is the same recipe it tested successfully in older adults and it plans to seek Food and Drug Administration approval for those vaccinations by year's end.

1 year ago·Toronto, Canada

Read Full Article

abc News

Strong RSV vaccine data lifts hopes after years of futility

A new study suggests vaccinating pregnant women protects their newborns from the common but scary respiratory virus called RSV

1 year ago·United States

Read Full Article

CNN

After promising trial results for maternal RSV vaccine, Pfizer says it will seek FDA approval this year

Pfizer says it has enough promising data on its respiratory syncytial virus, or RSV, vaccine designed to protect newborns that it will end enrollment in the study and submit for US Food and Drug Administration approval by the end of the year.

1 year ago·Atlanta, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.